Skip to main content

Table 6 Lymphocyte subpopulations in alemtuzumab (Alem)-treated patients and controls (CON)

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Cell count, median and range (×109/L)

Percentage of lymphocyte population

Previous cell count, median and range (×109/L)

Lymphocyte subpopulation

ALEM (n = 9*)

CON (n = 8)

P valuea

ALEM (n = 9*)

CON (n = 8)

ALEM cohort 2012 data (n = 20)

ALEM cohort 2001 data (n = 40)

Total lymphocytes

0.93 (0.41 − 3.1)

1.125 (0.34 − 2.38)

0.7001

n/a

n/a

1.15 (0.3 − 2.9)

n/a

CD4+ T cells

0.37 (0.13 − 0.94)

0.48 (0.13 − 0.65)

0.4406

30.5 (11.5 − 46.7)

34.9 (13.3 − 43.7)

0.55 (0.12 − 1.94)

0.000185

CD4+ naïve T cells

0.23 (0.01 − 0.61)

0.21 (0.07 − 0.29)

1

20.3 (1.23 − 30.5)

13.3 (4.15 − 20.6)

0.09 (0.01 − 0.65)

n/a

CD4+ total memory T cells

0.13 (0.11–0.34)

0.26 (0.06 − 0.56)

0.2359

12.52 (7.26 − 18.93)

18.5 (9.3 − 29.74)

0.37 (0.10 − 0.73)

n/a

CD4+ central memory T cells

0.08 (0.05 − 0.16)

0.2 (0.03 − 0.42)

0.0360

7.24 (4.74 − 13.28)

12.82 (6.73 − 22.45)

0.11 (0.02 − 0.07)

n/a

CD4+ effector memory T cells

0.05 (0.02–0.17)

0.06 (0.02 − 0.14)

0.9626

4.37 (1.81 − 7.58)

3.78 (2.42 − 7.56)

0.26 (0.07 − 0.55)

n/a

CD8+ T cells

0.10 (0.04 − 0.72)

0.11 (0.05 − 0.42)

0.9626

7.27 (4.95 − 31.9)

9.04 (3.96 − 22.7)

0.25 (0.02 − 0.78)

0.00009

CD8+ naïve T cells

0.05 (0.01 − 0.14)

0.02 (0.01 − 0.08)

0.2766

3.32 (0.46 − 7.27)

1.57 (0.64 − 5.94)

0.05 (0.001 − 0.17)

n/a

CD8+ total memory T cells

0.02 (0.07 − 0.13)

0.06 (0.01 − 0.19)

0.0592

1.82 (0.72 − 4.41)

3.97 (0.62 − 0.55)

0.12 (0.01 − 0.41)

n/a

CD8+ central memory T cells

0.01 (0.003 − 0.01)

0.02 (0.005 − 0.11)

0.0274

0.69 (0.26 − 1.33)

1.84 (0.34 − 6.01)

0.02 (0.003 − 0.12)

n/a

CD8+ effector memory T cells

0.01 (0.007–0.07)

0.03 (0.007 − 0.1)

0.1672

1.51 (0.45 − 3.2)

1.94 (0.31 − 5.72)

0.07 (0.01 − 0.37)

n/a

B cells

0.01 (0.01 − 0.05)

0.09 (0.02 − 0.2)

0.0041

1.7 (1.12 − 4.15)

8.96 (4.64 − 17.5)

0.08 (0.02 − 0.26)

0.000115

Naïve B cells

0.01 (0.001–0.02)

0.08 (0.7 − 0.14)

0.0041

1.18 (0.71 − 2.69)

5.47 (3.62 − 16.4)

0.06 (0.01 − 0.23)

n/a

Memory B cells

0.006 (0.002 − 0.02)

0.01 (0.008–0.03)

0.1282

0.56 (0.37 − 0.86)

1.19 (0.22 − 3.91)

0.02 (0.002 − 0.19)

n/a

CD5+ B cells

0.001 (0.001 − 0.005)

0.03 (0.001 − 0.08)

0.0175

0.28 (0.084 − 0.94)

2.22 (0.33 − 3.48)

0.005 (0.0009 − 0.03)

n/a

CD19+CD24hiCD38hi

B cells

0.001 (0.00005 − 0.002)

0.009 (0.0008 − 0.038)

0.003

0.061 (0.014 − 0.42)

0.70 (0.51 − 2.31)

n/a

n/a

NK cells

0.1 (0.02 − 0.17)

0.07 (0.02 − 0.10)

0.4234

10.5 (3.3 − 19.2)

8.35 (4.84 − 13.3)

0.06 (0.01 − 0.2)

n/a

NK T cells

0.01 (0.0006–0.13)

0.009 (0.002 − 0.02)

0.6730

0.76 (0.12 − 4.34)

0.73 (0.52 − 1.27)

0.05 (0.003–0.27)

n/a

  1. Median values and ranges are displayed for both absolute number and percentage of lymphocyte population. a P value for alemtuzumab versus established rheumatoid arthritis cell count absolute number); values in italics are significant. Gating strategies were as follows: CD4+ T cells: CD3+CD4+; CD4+ naïve T cells: CD3+CD4+CD45RA+CD62L+; CD4+ total memory T cells: CD3+CD4+CD45RA-; CD4+ central memory T cells: CD3+CD4+CD45RA-CD62L+; CD4+ effector memory T cells: CD3+CD4+CD45RA-CD62L-; CD8+ T cells: CD3+CD4-, CD8+ naïve T cells: CD3+CD4-CD45RA+CD62L+; CD8+ total memory T cells: CD3+CD4-CD45RA-; CD8+ central memory T cells: CD3+CD4-CD45RA-CD62L+; CD4+ effector memory T cells: CD3+CD4-CD45RA-CD62L-; B cells: CD19+; Naïve B cells: CD19+CD27-; Memory B cells: CD19+CD27+; CD5+ B cells: CD19+CD5+; CD19+CD24hiCD38hi B cells: CD19+CD24hiCD38hi; NK Cells: CD3-CD56+, NK T Cells: CD3+CD56+. For comparison previous analyses (years 2001 and 2012) of lymphocyte subpopulations of the alemtuzumab cohort are included. *Single patient had rituximab within the preceding month and was excluded from B-cell analyses. NK natural killer. n/a not available